A Clinical Trial to Evaluate the Effect of Grapefruit Juice on the PK/PD of Edoxaban

Not Applicable

Recruiting

• Conditions: Healthy
• Interventions: Drug: Edoxaban 60 MG [Lixiana]; Other: Edoxaban 60 MG [Lixiana] + Grapefruit Juice

• Registration Number: NCT07113054
• Lead Sponsor: Hyewon Chung

Brief Summary

The aim of the study is to evaluate the effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of edoxaban in healthy adults

Detailed Description

Pharmacokinetics and pharmacodynamics of edoxaban without coadministration of grapefruit juice will be compared with those after administration of grapefruit juice.

Study Timeline

• Study First Submitted: 2025-08-01
• Study First Submitted QC: 2025-08-01
• Study First Posted: 2025-08-08
• Status Verified: 2025-09
• Study Start: 2025-09-01
• Primary Completion: 2025-09
• Study Completion: 2025-09-01
• Last Update Submitted: 2025-09-02
• Last Update Posted: 2025-09-03

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

• Adults aged 19 to 50 years of age (inclusive) at the time of screening
• Subjects with BMI of 18 to 32 kg/m2 (inclusive)
• Subjects who agree to use medically acceptable methods of contraception and not to donate sperm or oocyte
• Subjects who voluntarily decided to participate in the study and provided written consent to comply with the protocol

Exclusion Criteria

• Subjects with current or history of clinically significant cardiovascular, respiratory, hepatic, renal, hematological, gastrointestinal, endocrine, immunological, dermatological, or neuropsychiatric disease
• Subjects with current or history of clinically significant hypersensitivity reactions or hypersensitivity reactions to the components or constituents of the investigational product
• Subjects who have clinically significant hemorrhage or increased risk of hemorrhage due to the following conditions A. Recent history of gastrointesinal ulcers B. Malignant tumor with a high risk of bleeding C. Recent brain or spinal cord injury D. Recent brain, spinal cord, or opthalmic surgery E. Recent history of intracranial or intracerebral hemorrhage F. Esophageal varices, arterial malformations, vascular aneurysms, or spinal cord or cerebral vascular abnormalities G. Coagulation disorders, thrombocytopenia, or platelet dysfunction H. Recent biopsy or major trauma I. Bacterial endocarditis J. Esophagitis, Gastritis, or Gastroesophageal reflux
• Subjects with a history of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
• Subjects whose eGFR calculated by the CKD-EPI formula is 80mL/min or less at Screening
• Subjects whose AST or ALT levels are more than 2 times the upper limit of normal range, or total bilirubin levels are more than 1.5 times the upper limit of normal range at screening
• Subjects whose coagulation test (aPTT, PT) exceeds the normal range at screening
• Subjects who have taken the following medication or medication known to have significant drug interactions with the investigational product within the 2 weeks prior to the first administration day A. Strong P-gp inhibitor or inducer B. Acetylsalicylic acid, antiplatelet agent, anticoagulant, fibrinolytic agent, non-steroidal anti-inflammatory drug (NSAID), selective serotonin reuptake inhibitor (SSRI), or selective serotonin-norepinephrine reuptake inhibitor (SNRI)
• Subjects who donated whole blood within 60 days or blood components within 30 days, or received blood transfusion within 30 days prior to the first administration day
• Subjects who participated and have been exposed to an investigational product in other clinical study within 180 days prior to the first administration day
• Subjects who consistently consumed alcohol (alcohol 21 units/week [1 unit = 10 g of pure alcohol]) within 2 weeks of the first administration day
• Subjects who consumed grapefruit or grapefruit juice within 2 weeks of the first administration day
• Pregnant or breastfeeding women
• Subjects judged unsuitable to participate in the clinical study by investigators due to other reasons, including the results of laboratory tests

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Edoxaban and Grapefruit Juice	Edoxaban 60 MG [Lixiana]	* Period 1: Single dose of edoxaban 60 mg administered alone * Period 2: Single dose of edoxaban 60 mg coadministered with grapefruit juice 3 times daily for 3 days
Edoxaban and Grapefruit Juice	Edoxaban 60 MG [Lixiana] + Grapefruit Juice	* Period 1: Single dose of edoxaban 60 mg administered alone * Period 2: Single dose of edoxaban 60 mg coadministered with grapefruit juice 3 times daily for 3 days

Primary Outcome Measures

Name	Time	Method
AUCinf	24 hours post-dose	Area under the concentration-time curve from time of administration extrapolated to infinity
Cmax	24 hours post-dose	maximum concentration
aPTT	24 hours post-dose	activated partial thromboplastin time
TGA	24 hours post-dose	Thrombin generation assay
PT	24 hours post-dose	prothrombin time

Trial Locations

Locations (1)

Korea University Guro Hospital; 🇰🇷 Seoul, Seoul, South Korea